EMA Authorised: Erbitux (cetuximab) — Merck Europe B.V.

View source ↗

Summary

EMA authorised Erbitux (cetuximab) for head and neck cancer and colorectal cancer under Merck Europe B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Status: Authorised. Therapeutic area: Head and Neck Neoplasms;Colorectal Neoplasms. MAH: Merck Europe B.V.. Decision date: 28/01/2026